Altered degradation of extracellular matrix in myocardial remodelling: The growing role of cathepsins and cystatins

Cardiovascular Research

Volumn 87, Issue 4, 2010, Pages 591-592

  Díez, Javier ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CATHEPSIN B; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYSTATIN; CYSTATIN C; CYSTEINE PROTEINASE; CYTOKINE; ELASTIN; GROWTH FACTOR; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; MESSENGER RNA; SCAFFOLD PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

EDITORIAL; EXTRACELLULAR MATRIX; FIBROBLAST; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HUMAN; LYSOSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS;

ANIMALS; CATHEPSINS; COLLAGEN TYPE I; COLLAGEN TYPE III; CYSTATIN C; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBRONECTINS; HEART DISEASES; MICE; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROTEOMICS; RATS; TIME FACTORS; UP-REGULATION; VENTRICULAR REMODELING;

EID: 77955912195     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq208     Document Type: Editorial

References (15)

1. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989;13:1637-1652.
2. Obermajer N, Jevnikar Z, Doljak B, Kos J. Role of cysteine cathepsins in matrix degradation and cell signalling. Connect Tissue Res 2008;49:193-196.
3. Punturieri A, Filippov S, Allen E, Caras I, Murray R, Reddy V et al. Regulation of elas-tinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med 2000;192:789-799.
4. Turk V, Stoka V, Turk D. Cystatins: biochemical and structural properties, and medical relevance. Front Biosci 2008;13:5780-5786.
5. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysm. J Clin Invest 1999;104: 1191-1197.
6. Cheng XW, Murohara T, Kuzuya M, Izawa H, Sasaki T, Obata K et al. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol 2008;173:358-369.
7. Cheng XW, Obata K, Kuzuya M, Izawa H, Nakamura K, Asahi E et al. Elastolytic cath-epsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 2006;48:979-987.
8. Barka T, van der Noen H. Expression of the cysteine proteinase inhibitor cystatin C gene in rat heart: use of digoxigenin-labeled probes generated by polymerase chain reaction directly for in situ and Northern blot hybridizations. J Histochem Cytochem 1993;41:1863-1867.
9. Stypmann J, Gläser K, Roth W, Tobin DJ, Petermann I, Mathias R et al. Dilated cardi-omyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci USA 2002;99:6234-6239.
10. Ge J, Zhao G, Chen R, Li S, Wang S, Zhang X et al. Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy. Eur J Heart Fail 2006;8:284-289.
11. Xie L, Terrand J, Xu B, Tsaprailis G, Boyer J, Chen QM. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc Res 2010;87: 628-635.
12. Dhalla NS, Sainin-Chohan HK, Rodriguez-Leyva D, Elimban V, Dent MR, Tappia PS. Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. Cardiovasc Res 2009;81:429-438.
13. Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail 2009;2:98-104.
14. Djoussé L, Kurth T, Gaziano JM. Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J 2008;155:82-86.
15. Gupta S, Drazner MH, de Lemos JA. Newer biomarkers in heart failure. Heart Fail Clin 2009;5:579-588.